Bahena-Carrera L

Language: Spanish
References: 11
Page: 107-109
PDF size: 189.94 Kb.

REFERENCES

1. Altobelli C, Anastasio P, Cerrone A, Signoriello E, Lus G, Pluvio C et al. Therapeutic plasmapheresis: a revision of literature. Kidney Blood Press Res. 2023; 48 (1): 66-78.

2. Marfo K, Lu A, Ling M, Akalin E. Desensitization protocols and their outcome. Clin J Am Soc Nephrol. 2011; 6 (4): 922-936.

3. Jordan SC, Choi J, Vo A. Kidney transplantation in highly sensitized patients. Br Med Bull. 2015; 114 (1): 113-125.

4. Chung BH, Choi BS, Oh EJ, Park CW, Kim JI, Moon IS et al. Clinical impact of the baseline donor-specific anti-human leukocyte antigen antibody measured by Luminex single antigen assay in living donor kidney transplant recipients after desensitization therapy. Transpl Int. 2014; 27 (1): 49-59.

5. Jordan SC, Vo AA, Nast CC, Tyan D. Use of high-dose human intravenous immunoglobulin therapy in sensitized patients awaiting transplantation: the Cedars-Sinai experience. Clin Transpl. 2003: 193-198.

6. Macklin PS, Morris PJ, Knight SR. A systematic review of the use of rituximab for desensitization in renal transplantation. Transplantation. 2014; 98 (8): 794-805.

7. Jordan SC, Legendre C, Desai NM, Lorant T, Bengtsson M, Lonze BE et al. Imlifidase desensitization in crossmatch-positive, highly sensitized kidney transplant recipients: results of an International Phase 2 trial (Highdes). Transplantation. 2021; 105 (8): 1808-1817.

8. Marks WH, Mamode N, Montgomery RA, Stegall MD, Ratner LE, Cornell LD et al. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: a randomized trial. Am J Transplant. 2019; 19 (10): 2876-2888.

9. Vo AA, Choi J, Kim I, Louie S, Cisneros K, Kahwaji J et al. A phase I/II trial of the interleukin-6 receptor-specific humanized monoclonal (Tocilizumab) + intravenous immunoglobulin in difficult to desensitize patients. Transplantation. 2015; 99 (11): 2356-2363.

10. Torija A, Matignon M, Vincenti F, Casanova-Ferrer F, Pilon C, Tambur AR et al. Anti-HLA serologic response to CD38-targeting desensitization therapy is challenged by peripheral memory B cells in highly sensitized kidney transplant candidates. Am J Transplant. 2025; 25 (1): 88-101.

11. Montgomery RA. Renal transplantation across HLA and ABO antibody barriers: integrating paired donation into desensitization protocols. Am J Transplant. 2010; 10 (3): 449-457.